卖什么
The agentic drug company. We simulate human biology.
商业模式拆解
买家：谁掌握预算？
未核实Heads of R&D / translational science at pharma and biotech.
触发点：什么让他们现在购买？
Need to prioritize compounds before expensive physical assays and kill unsafe programs before clinic.
工作流：什么输入变成什么输出？
Virtual compound screening, cross-species transfer to predict human toxicity, and linking preclinical interventions to patient evidence for responder signatures and trial design; model fine-tuned on customer proprietary assays.
经济账：省了什么，怎么收费？
Likely enterprise platform licence or partnership deployed on-prem or in customer VPC; no prices shown. Validation claim: 4,266 compounds screened, 23 prioritized, 3 validated hits in ex-vivo tumor tissue.
渠道：怎么接触到客户？
未核实Partnership-led ('Partner with us'); enterprise direct deployment.
融资历史与报道
| 融资日期 | 轮次 | 金额 | 投资方 | 来源 |
|---|---|---|---|---|
| — | YC 2026 冬季 | — | Y Combinator | ycombinator.com |
档案汇总自公开报道和公司官网。商业模式部分是 MaxBC 对这些材料的解读，不是已确认的事实；未知之处留空，不作猜测。 更新于 2026-10-12.